Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 136 participants.
Also called NCT02010242
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 136 participants
- Sponsor
- Asahi Kasei Therapeutics, AB
- Registry
-
NCT02010242
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, Czechia, Germany, Poland
- Registry status
- Completed
Technical summary
Registry record NCT02010242. Randomized; quadruple masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2015-02 (actual). Results posted on 2025-02-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
- Condition
- Type 2 Diabetes Mellitus With Diabetic Nephropathy
- Intervention (Drug)
- GKT137831
- Intervention (Drug)
- Placebo
- Lead sponsor
- Asahi Kasei Therapeutics, AB
Record details
- Record id
cardio:ct-nct02010242- Content hash
679df41ed2a5f1b4e2b9df5cdb0af8485c2bebc4e13b9fcb1521712ecbfd1328